Gender difference in response predictors after 1-year exenatide therapy twice daily in type 2 diabetic patients: a real world experience
Roberto Anichini,1 Sabrina Cosimi,2 Alberto Di Carlo,3 Paola Orsini,4 Alessandra De Bellis,1 Giuseppe Seghieri,1 Flavia Franconi,5 Fabio Baccetti6 1Diabetes Unit, Spedali Riuniti, Pistoia, Italy; 2Diabetes Unit, Hospital of Versilia, Camaiore (LU), Italy; 3Diabetes Unit, Hospital of Lucca, Italy; 4D...
Main Authors: | Anichini R, Cosimi S, Di Carlo A, Orsini P, De Bellis A, Seghieri G, Franconi F, Baccetti F |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-04-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Online Access: | http://www.dovepress.com/gender-difference-in-response-predictors-after-1-year-exenatide-therap-a12685 |
Similar Items
-
Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
by: McDonell AL, et al.
Published: (2015-01-01) -
Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
by: Yuusuke Watanabe, et al.
Published: (2020-03-01) -
Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus
by: Jie Zhang, et al.
Published: (2022-01-01) -
Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
by: Chiquette E, et al.
Published: (2012-11-01) -
Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety.
by: Catherine G Derington, et al.
Published: (2020-01-01)